The effects of resveratrol on markers of oxidative stress in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial

• Published in: Acta diabetologica Vol. 55; no. 4; pp. 341 - 353
• Main Authors: Seyyedebrahimi, ShadiSadat, Khodabandehloo, Hadi, Nasli Esfahani, Ensieh, Meshkani, Reza
• Format: Journal Article
• Language: English
• Published: Milan Springer Milan 01.04.2018; Springer Nature B.V
• Subjects: Adult; Aged; Antioxidants; Antioxidants - pharmacology; Biomarkers - analysis; Biomarkers - blood; Blood pressure; Body Weight - drug effects; C-Reactive Protein - metabolism; Clinical trials; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - metabolism; Dietary Supplements; Double-Blind Method; Double-blind studies; Female; Humans; Hydrogen peroxide; Hydrogen Peroxide - blood; Internal Medicine; IRCT; IRCT2015072523336N1; Male; Malondialdehyde; Malondialdehyde - blood; Medicine; Medicine & Public Health; Metabolic Diseases; Metabolism; Middle Aged; Nitric-oxide synthase; Original Article; Oxidative stress; Oxidative Stress - drug effects; Placebos; Protein Carbonylation - drug effects; Resveratrol; Stilbenes - pharmacology; Superoxide; Supplements; Type 2 diabetes; Oxidative stress; Nrf2; Resveratrol; ROS; Clinical trial; PBMC
• ISSN: 0940-5429; 1432-5233; 1432-5233
• DOI: 10.1007/s00592-017-1098-3

Aims Oxidative stress plays a pivotal role in the pathogenesis of type 2 diabetes (T2D). In vitro and animal studies have shown that resveratrol exerts an antioxidant effect, but clinical trials addressing this effect in patients with T2D are limited. The aim of this study was to determine whether resveratrol supplementation affects oxidative stress markers in a randomized, placebo-controlled, double-blind clinical trial. Methods A total of 48 patients with T2D randomly were assigned to receive 800 mg/day resveratrol or placebo for 2 months. Plasma total antioxidant capacity, malondialdehyde concentration, protein carbonyl and total thiol contents, intracellular superoxide anion (O 2 − ·) and hydrogen peroxide (H 2 O 2 ) in PBMCs, the expression of genes involved in oxidative stress responses (Nrf2, SOD, Cat, HO-1, RAGE, NOS) in PBMCs, and metabolic and anthropometric parameters were measured at the baseline and at the trial end. Results Compared with the placebo group, resveratrol reduced plasma protein carbonyl content and PBMCs O 2 − · level and significantly increased plasma total antioxidant capacity and total thiol content. Furthermore, the expression of Nrf2 and SOD was significantly increased after resveratrol consumption. Resveratrol had no significant effects on the metabolic and anthropometric parameters except for a significant reduction in weight, BMI, and blood pressure levels. Resveratrol was well tolerated, and no serious adverse event was occurred. Conclusions Our study demonstrated that 8 weeks of supplementation with 800 mg/day resveratrol has an antioxidant effect in the blood and PBMCs of patients with T2D. Clinical Trial Registry number and website IRCT registration number: IRCT2015072523336N1 and http://en.search.irct.ir/view/24752 .